Ormutivimab

Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model[1][2].

Research Areas >> Infection

Signaling Pathways >> Others >> Others

Ormutivimab (20 IU/kg；肌肉注射；单剂量) 保护比格犬免受 RABV BD06 的致命攻击[1]。 Ormutivimab (20 IU/kg、100 IU/kg；肌注；单剂量) 保护受攻击的 Kunming 小鼠免受各种狂犬病病毒的侵害[1]。 Animal Model: Balb/c mice challenge model with rabies virus[1] Dosage: 20 IU/kg, 100 IU/kg Administration: Intramuscular injection; single dose after 4 hr after infection Result: Protected mice from rabies CVS-24 and GZ-1 isolates at a comparable rate (90%) to that of HRIG, human antirabies immune globulin.

[1]. Zhai LL, et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med Infect Dis. 2022 Mar-Apr;46:102267.  

[2]. Zhang J, et al. Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects. Vaccines (Basel). 2022 Jul 29;10(8):1218.